Please assess the completion status of the following clinical trial:

Trial Title: A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* 3 or more episodes of acute VVC in the past 12 months~* Positive KOH or Gram stain~* Total vulvovaginal signs and symptoms score of ≥3 at screening visit~* Total vulvovaginal signs and symptoms score of \<3 at baseline visit~* Must be able to swallow pills~Key Exclusion Criteria:~* Presence or a history of another vaginal or vulvar condition(s)~* Evidence of major organ system disease~* History of cervical cancer~* Poorly controlled diabetes mellitus~* Pregnant~* Recent use of topical or systemic antifungal or antibacterial drugs~* Recent use of immunosuppressive or systemic corticosteroid therapies

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oteseconazole (VT-1161) 150mg capsule (Type: EXPERIMENTAL): Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
- Placebo capsule (Type: PLACEBO_COMPARATOR): Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).